Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
about
Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseMonoacylglycerol lipase - a target for drug development?A Binding Site for Nonsteroidal Anti-inflammatory Drugs in Fatty Acid Amide HydrolaseFatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disordersElevating endocannabinoid levels: pharmacological strategies and potential therapeutic applicationsParabens inhibit fatty acid amide hydrolase: A potential role in paraben-enhanced 3T3-L1 adipocyte differentiationCharacterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase InhibitorA chemical genetic screen uncovers a small molecule enhancer of the N-acylethanolamine degrading enzyme, fatty acid amide hydrolase, in ArabidopsisRole of Cannabinoids in Gastrointestinal Mucosal Defense and InflammationEffects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.Peripheral gating of pain signals by endogenous lipid mediators.Naproxen and Diclofenac Attenuate Atorvastatin-induced Preconditioning of the Myocardium.Acute Δ(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in miceCharacterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolismEnhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modalityCombined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models.Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays.Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice.Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice.Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in miceThe fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeysMultitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.Repeated psychological stress-induced alterations of visceral sensitivity and colonic motor functions in mice: influence of surgery and postoperative single housing on visceromotor responsesInteraction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding ModeCannabinoid receptors: nomenclature and pharmacological principlesThe fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide.A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model.Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.Cannabinoid system and cyclooxygenases inhibitorsTargeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies.Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not "higher".
P2860
Q24620186-54BA12CE-F0D1-4C18-9157-60A72E7CD138Q26998964-9FD31082-81F9-441C-AAA9-B9CBA0CA61B9Q27675504-B83B6D25-D957-4FC2-B0C8-7F3CB5A75DE9Q28285103-E6BA694E-841B-437D-848A-DF9DB5E47516Q28300390-85BED36E-582A-4A1A-8F83-DB89E1668E83Q28393331-3E1DBFCC-6C18-4AB4-8F83-867E97B5D269Q28548509-F1DCAD5A-485E-415A-B591-27222906286FQ28818594-7C552649-E106-4C9D-873D-CD4946BEFA1FQ30357558-51A244EB-3531-42EA-B30A-F90C445E0951Q30574567-6736F215-8409-4E41-8D84-5A57F8891979Q30733453-6DE61F66-4456-4645-B1CE-89A8A9D5AC70Q33608432-62056804-1297-4BD8-A519-376A65F98268Q33732277-D66BA808-EAB0-4818-B4A2-F488A9CF69B3Q33739530-579AD8BC-D3AA-4FC4-96EE-F3092309895DQ33840797-734231AC-BA15-42D3-B024-7765B39A07B8Q34018061-27DE7CF3-668C-4D9C-818C-094384CDEA49Q34390806-54C9FA0F-7FB2-4284-9E59-24E8A06F3C49Q34442314-09E585B7-5732-4F12-95D6-9893D29A5B41Q34644485-4E196085-7EF1-496B-B54D-AEE5543323DCQ35178237-0B66266A-76C8-4842-840C-06388EABF5DCQ35188129-07CC9408-2F64-4B8F-97CE-438DACE37DCDQ35189004-3AABEB09-E2A4-40B1-83F7-22EA2AA1F65FQ35223920-C9469C17-0C2D-4081-A6DE-D982132954DAQ35287465-26B7A7CA-A62E-4539-89E0-72CBBD1E3501Q35660108-F725CE6E-C09D-47B0-A1C1-E44C66981302Q35809355-52F38DBB-C52F-4A6A-8CD2-C6E080B2B6E6Q35840682-24EF64FE-39FA-4C77-A54E-24FE6D1771A0Q36044310-FF9207CE-54ED-415F-8826-6A8052DF925CQ36176531-E31F0B82-3EAF-4C86-832D-2DBE38CD034CQ36576347-DBCE1B84-6AD9-425C-A039-B2094E0A3655Q36712224-763AEF73-F770-44B0-A2A7-1D13C09781F6Q36823364-29C93347-A434-4A19-BCF3-5439E8235E52Q36852591-73F3FF9A-7537-4104-9DE2-4BA341AC6201Q36953261-B2127B69-DA2C-44C0-8F92-FAB2E120B10EQ37030457-EB734297-820D-4D60-B398-D860818647D0Q37082114-CAFC5F3E-A208-4EEA-B60F-73981EFA766DQ37637750-406929DF-0DAF-4F23-934F-73D9C5450047Q37866994-0555AC29-AC5E-4CC5-B568-2BA9C8B281AEQ37960078-CB343921-6E3B-44A8-83A3-5350D420BE78Q38196875-A1BDA0F1-82EF-488C-AE0B-9235B3DCA794
P2860
Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synergy between enzyme inhibit ...... enase in visceral nociception.
@en
Synergy between enzyme inhibit ...... enase in visceral nociception.
@nl
type
label
Synergy between enzyme inhibit ...... enase in visceral nociception.
@en
Synergy between enzyme inhibit ...... enase in visceral nociception.
@nl
prefLabel
Synergy between enzyme inhibit ...... enase in visceral nociception.
@en
Synergy between enzyme inhibit ...... enase in visceral nociception.
@nl
P2093
P2860
P356
P1476
Synergy between enzyme inhibit ...... enase in visceral nociception.
@en
P2093
Aron H Lichtman
Lamont Booker
Pattipati S Naidu
P2860
P356
10.1124/JPET.108.143487
P407
P577
2008-12-31T00:00:00Z